Yesterday, the EVP of Danaher (DHR), Daniel Comas, sold shares of DHR for $3.02M.
In addition to Daniel Comas, 5 other DHR executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Danaher’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $4.34 billion and quarterly net profit of $595 million. In comparison, last year the company earned revenue of $4.22 billion and had a net profit of $334 million. The company has a one-year high of $170.64 and a one-year low of $119.60. DHR’s market cap is $115 billion and the company has a P/E ratio of 37.20.
Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $174.88, reflecting a -7.4% downside.
In the last 30 days, insiders have sold $16.37M worth of DHR shares and purchased $199.8K worth of DHR shares. The insider sentiment on Danaher has been negative according to 68 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician’s offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.
Read More on DHR:
